Influenza Vaccine To Prevent Adverse Vascular Events:Pilot

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT01945268

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01945268
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mozambique, Philippines, Uganda (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01945268. Randomized; quadruple masking; primary purpose treatment. Start 2015-04 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Influenza Vaccine To Prevent Adverse Vascular Events:Pilot
Acronym
IVVE:Pilot
Condition
Heart Failure
Intervention (Drug)
inactivated trivalent influenza vaccine
Intervention (Other)
Sterile saline
Lead sponsor
McMaster University (class: other)
Collaborator
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct01945268
Content hash
fa14facb58d99117dd646a5c5cad1b054d67db0108d8d6fa511b3a0e9e780e2b